- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02916017
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis)
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Kagoshima, Japan, 890-8520
- Kagoshima Uni Med and Dental /ID# 164150
-
Kakogawa, Japan, 489-0065
- Kakogawa Central City Hospital /ID# 167706
-
Miyakonojo, Japan, 885-0051
- Miyata Ophthalmic Hospital /ID# 167707
-
Nishinomiya-shi, Japan, 663-8501
- Duplicate_The Hospital of Hyogo College /ID# 166913
-
Omihachiman, Japan, 523-0082
- Omihachiman Community Med Ctr /ID# 164978
-
Osaka, Japan, 572-0854
- Osaka Hospital /ID# 164151
-
Osaka-shi, Japan
- Yodogawa Christian Hospital /ID# 161741
-
Seto, Japan, 489-8642
- Tosei General Hospital /ID# 167708
-
Tokorozawa, Japan, 359-0042
- Natl Defense Med College Hosp /ID# 162946
-
Tokyo, Japan, 108-6303
- Abbott Japan /ID# 147893
-
Tokyo, Japan, 162-8543
- Tokyo Shinjuku Medical Center /ID# 166934
-
Tottori, Japan, 680-8501
- Tottori Municipal Hospital /ID# 159431
-
-
Chiba
-
Urayasu-shi, Chiba, Japan, 279-0021
- Juntendo University Urayasu Hospital /ID# 168358
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 790-0826
- Matsuyama Red Cross Hospital /ID# 164149
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 812-8582
- Kyushu University Hospital /ID# 163042
-
Fukuoka-shi, Fukuoka, Japan, 814-0180
- Fukuoka University Hospital /ID# 163043
-
Kurume-shi, Fukuoka, Japan, 830-0011
- Kurume University Hospital /ID# 162945
-
-
Gunma
-
Maebashi-shi, Gunma, Japan, 371-8511
- Gunma University Hospital /ID# 166916
-
-
Hiroshima
-
Hiroshima-shi, Hiroshima, Japan, 734-8551
- Hiroshima University Hospital /ID# 166915
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8648
- Hokkaido University Hospital /ID# 163041
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan, 650-0017
- Kobe University Hospital /ID# 165250
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan, 920-8641
- Duplicate_Kanazawa University Hospital /ID# 166914
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 240-8555
- Yokohama Municipal Citizen's Hospital /ID# 161742
-
-
Kochi
-
Nankoku-shi, Kochi, Japan, 783-8505
- Kochi Medical School Hospital /ID# 164144
-
-
Nagano
-
Matsumoto-shi, Nagano, Japan, 390-8621
- Shinshu University Hospital /ID# 164153
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 951-8520
- Niigata University Medical & Dental Hospital /ID# 169563
-
-
Osaka
-
Suita-shi, Osaka, Japan, 565-0871
- Osaka University Hospital /ID# 164147
-
-
Saitama
-
Iruma-gun, Saitama, Japan, 350-0451
- Saitama Medical University Hospital /ID# 162944
-
-
Tochigi
-
Shimotsuga-gun, Tochigi, Japan, 321-0293
- Dokkyo Medical University Hospital /ID# 164154
-
-
Tokushima
-
Tokushima-shi, Tokushima, Japan, 770-8503
- Tokushima University Hospital /ID# 164145
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8431
- Juntendo University Hospital /ID# 169564
-
Bunkyo-ku, Tokyo, Japan, 113-8519
- Tokyo Medical And Dental University, Medical Hospital /ID# 165251
-
Bunkyo-ku, Tokyo, Japan, 113-8603
- Nippon Medical School Hospital /ID# 166938
-
Bunkyo-ku, Tokyo, Japan, 113-8655
- The University of Tokyo Hospital /ID# 162943
-
Minato-ku, Tokyo, Japan, 105-8471
- The Jikei University Hospital /ID# 164152
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital /ID# 164146
-
Shinjuku-ku, Tokyo, Japan, 162-8655
- Center Hospital of the National Center for Global Health and Medicine /ID# 164148
-
Shinjuku-ku, Tokyo, Japan, 162-8666
- Tokyo Women's Medical University Hospital /ID# 165248
-
-
Yamaguchi
-
Ube-shi, Yamaguchi, Japan, 755-8505
- Yamaguchi University Hospital /ID# 165249
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Exclusion Criteria:
- Participants previously treated with adalimumab
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
---|
Participants receiving adalimumab
Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Incidence of adverse drug reactions (ADR)
Tijdsspanne: Up to Week 52
|
ADR is the causal relationship between adalimumab and adverse events.
|
Up to Week 52
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in Visual Functioning Questionnaire (VFQ)-25 score
Tijdsspanne: From Week 0 (baseline) to Week 52
|
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning.
The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question.
The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
|
From Week 0 (baseline) to Week 52
|
Change in Visual acuity in each eye
Tijdsspanne: From Week 0 (baseline) to Week 52
|
Visual acuity change is assessed.
|
From Week 0 (baseline) to Week 52
|
Change in Anterior Chamber (AC) cell grade (standardization of uveitis nomenclature (SUN) criteria) in each eye
Tijdsspanne: From Week 0 (baseline) to Week 52
|
Slit lamp examinations will be conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam will be used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = < 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = > 50 cells. |
From Week 0 (baseline) to Week 52
|
Percentage of Overall improvement
Tijdsspanne: Up to Week 52
|
This is assessed by physicians.
|
Up to Week 52
|
Change in retinal lesions in each eye
Tijdsspanne: From Week 0 (baseline) to Week 52
|
The change in retinal lesion are assessed.
|
From Week 0 (baseline) to Week 52
|
Change in central retinal thickness in each eye
Tijdsspanne: From Week 0 (baseline) to Week 52
|
This is assessed by Optical Coherence Tomography (OCT)
|
From Week 0 (baseline) to Week 52
|
Change in Vitreous Haze grade in each eye
Tijdsspanne: From Week 0 (baseline) to Week 52
|
Vitreous haze will be measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI)/ SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured. |
From Week 0 (baseline) to Week 52
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- P15-665
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .